RT Journal Article
SR Electronic
A1 Rizzo, Toni
T1 ESTEEM 2: Apremilast Significantly Reduced Psoriasis Severity Throughout 16 Weeks
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 37
SP 15
OP 16
DO 10.1177/155989771437012
UL http://mdc.sagepub.com/content/14/37/15.abstract
AB Apremilast, an oral phosphodiesterase 4 inhibitor that works intracellularly to regulate inflammatory mediators, has been tested in the Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) program, which consists of 2 trials: ESTEEM 1 [NCT01194219] and ESTEEM 2 [NCT01232283]. This article presents the 52-week results of the ESTEEM 2 trial.